FDA center structure may be ripe for reorganization, deputy commissioner suggests.
This article was originally published in The Tan Sheet
Executive Summary
FDA CENTER STRUCTURE REVISION SHOULD BE CONSIDERED, DEPUTY COMMISSIONER Mary Pendergast suggested during a May 7 Food & Drug Law Institute meeting in Washington, D.C. "As technology becomes a seamless web, and not the old chemical drugs, biological drugs and mechanical things, as we realize that there is a seamless web of products out there, we have to continue to work to be a seamless web of an agency," Pendergast said. The upcoming appointment of a new FDA commissioner presents a logical opportunity for another review of FDA's structural lay-out.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning